{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:14:10Z","timestamp":1788459250740,"version":"build-2803163510"},"reference-count":30,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,7,28]]},"DOI":"10.2967\/jnumed.126.272607","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:25:22Z","timestamp":1788456322000},"page":"jnumed.126.272607","source":"Crossref","is-referenced-by-count":0,"title":["A Prospective, Single-Center, Single-Arm, Exploratory Study of\n                    <sup>177<\/sup>\n                    Lu-LNC1010 Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors"],"prefix":"10.2967","author":[{"given":"Wei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanming","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026090310251741000_jnumed.126.272607v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2026090310251741000_jnumed.126.272607v1.2","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"key":"2026090310251741000_jnumed.126.272607v1.3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0488"},{"key":"2026090310251741000_jnumed.126.272607v1.4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.thorsurg.2014.04.005","article-title":"Peptide receptor radionuclide therapy for advanced neuroendocrine tumors","volume":"24","author":"Bodei","year":"2014","journal-title":"Thorac Surg Clin."},{"key":"2026090310251741000_jnumed.126.272607v1.5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7150\/thno.23491","article-title":"Evans blue attachment enhances somatostatin receptor subtype-2 imaging and radiotherapy","volume":"8","author":"Tian","year":"2018","journal-title":"Theranostics."},{"key":"2026090310251741000_jnumed.126.272607v1.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.209841"},{"key":"2026090310251741000_jnumed.126.272607v1.7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.apsb.2024.05.022","article-title":"Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: from preclinical testing to first-in-human study","volume":"15","author":"Guo","year":"2025","journal-title":"Acta Pharm Sin B."},{"key":"2026090310251741000_jnumed.126.272607v1.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259192"},{"key":"2026090310251741000_jnumed.126.272607v1.9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-27994-2_30"},{"key":"2026090310251741000_jnumed.126.272607v1.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"},{"key":"2026090310251741000_jnumed.126.272607v1.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.248658"},{"key":"2026090310251741000_jnumed.126.272607v1.12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00259-023-06383-1","article-title":"A phase I\/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours","volume":"51","author":"Wild","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026090310251741000_jnumed.126.272607v1.13","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1007\/s00259-019-04389-2","article-title":"Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide\/chemoradionuclide therapy (PRRT\/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series","volume":"46","author":"Goncalves","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026090310251741000_jnumed.126.272607v1.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.107524"},{"key":"2026090310251741000_jnumed.126.272607v1.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1026"},{"key":"2026090310251741000_jnumed.126.272607v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2026090310251741000_jnumed.126.272607v1.17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.7150\/thno.92487","article-title":"Long-term nephrotoxicity after PRRT: myth or reality","volume":"14","author":"Baum","year":"2024","journal-title":"Theranostics."},{"key":"2026090310251741000_jnumed.126.272607v1.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264533"},{"key":"2026090310251741000_jnumed.126.272607v1.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.258889"},{"key":"2026090310251741000_jnumed.126.272607v1.20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00432-020-03181-2","article-title":"The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis","volume":"146","author":"Zhang","year":"2020","journal-title":"J Cancer Res Clin Oncol."},{"key":"2026090310251741000_jnumed.126.272607v1.21","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0424"},{"key":"2026090310251741000_jnumed.126.272607v1.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.256727"},{"key":"2026090310251741000_jnumed.126.272607v1.23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/MNM.0000000000000685","article-title":"Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET","volume":"38","author":"Pencharz","year":"2017","journal-title":"Nucl Med Commun."},{"key":"2026090310251741000_jnumed.126.272607v1.24","doi-asserted-by":"crossref","first-page":"e70013","DOI":"10.1111\/jne.70013","article-title":"Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors","volume":"37","author":"Santo","year":"2025","journal-title":"J Neuroendocrinol."},{"key":"2026090310251741000_jnumed.126.272607v1.25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2967\/jnumed.118.224386","article-title":"Parameters to predict progression-free and overall survival after peptide receptor radionuclide therapy: a multivariate analysis in 782 patients","volume":"60","author":"Aalbersberg","year":"2019","journal-title":"J Nucl Med."},{"key":"2026090310251741000_jnumed.126.272607v1.26","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.7150\/thno.77219","article-title":"Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors","volume":"12","author":"Jiang","year":"2022","journal-title":"Theranostics."},{"key":"2026090310251741000_jnumed.126.272607v1.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265391"},{"key":"2026090310251741000_jnumed.126.272607v1.28","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2967\/jnumed.120.248062","article-title":"Combination strategies to improve targeted radionuclide therapy","volume":"61","author":"Chan","year":"2020","journal-title":"J Nucl Med."},{"key":"2026090310251741000_jnumed.126.272607v1.29","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1007\/s00259-024-06844-1","article-title":"Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer","volume":"51","author":"Rauch","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026090310251741000_jnumed.126.272607v1.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262344"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:25:24Z","timestamp":1788456324000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":30,"alternative-id":["10.2967\/jnumed.126.272607"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272607","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}